MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study / Ascierto, P; Schadendorf, D; Berking, C; Agarwala, Ss; Van Herpen, Cml; Queirolo, P; Blank, Cu; Hauschild, A; Beck, Jt; St-Pierre, A; Niazi, F; Wandel, S; Peters, M; Zubel, A; Dummer, R. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - 14:3(2013), pp. 249-256. [10.1016/S1470-2045(13)70024-X]

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Ascierto P;
2013

2013
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study / Ascierto, P; Schadendorf, D; Berking, C; Agarwala, Ss; Van Herpen, Cml; Queirolo, P; Blank, Cu; Hauschild, A; Beck, Jt; St-Pierre, A; Niazi, F; Wandel, S; Peters, M; Zubel, A; Dummer, R. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - 14:3(2013), pp. 249-256. [10.1016/S1470-2045(13)70024-X]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014582
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact